Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1988 1
1989 1
1992 1
1993 2
1994 2
1995 3
1996 7
1997 3
1998 3
1999 6
2000 4
2001 7
2002 2
2003 8
2004 12
2005 2
2006 7
2007 7
2008 12
2009 14
2010 15
2011 12
2012 10
2013 12
2014 15
2015 21
2016 26
2017 22
2018 22
2019 25
2020 26
2021 38
2022 23
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Džavík V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le G… See abstract for full author list ➔ REMAP-CAP Investigators, et al. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34351722 Free PMC article. Clinical Trial.
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Myers RM, et al. J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12. J Clin Oncol. 2022. PMID: 34767461 Free PMC article.

Among patients evaluable for CD19-CAR response (n = 412), blinatumomab nonresponders had lower complete remission rates to CD19-CAR (20 of 31, 64.5%) than blinatumomab responders (39 of 42, 92.9%) or blinatumomab-naive patients (317 of 339, 93.5%), P < .0001. Following

…
Among patients evaluable for CD19-CAR response (n = 412), blinatumomab nonresponders had lower complete remission rates to CD19-CAR (20 of 3 …
Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
HIP ATTACK Investigators. HIP ATTACK Investigators. Lancet. 2020 Feb 29;395(10225):698-708. doi: 10.1016/S0140-6736(20)30058-1. Epub 2020 Feb 9. Lancet. 2020. PMID: 32050090 Clinical Trial.
The median time from hip fracture diagnosis to surgery was 6 h (IQR 4-9) in the accelerated-surgery group and 24 h (10-42) in the standard-care group (p<0.0001). 140 (9%) patients assigned to accelerated surgery and 154 (10%) assigned to standard care died, with a hazar …
The median time from hip fracture diagnosis to surgery was 6 h (IQR 4-9) in the accelerated-surgery group and 24 h (10-42) in the standard-c …
Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial.
Vaara ST, Ostermann M, Bitker L, Schneider A, Poli E, Hoste E, Fierens J, Joannidis M, Zarbock A, van Haren F, Prowle J, Selander T, Bäcklund M, Pettilä V, Bellomo R; REVERSE-AKI study team. Vaara ST, et al. Intensive Care Med. 2021 Jun;47(6):665-673. doi: 10.1007/s00134-021-06401-6. Epub 2021 May 7. Intensive Care Med. 2021. PMID: 33961058 Free PMC article. Clinical Trial.
RESULTS: Mean (SD) cumulative fluid balance at 72 h from randomization was - 1080 mL (2003 mL) in the restrictive fluid management arm and 61 mL (3131 mL) in the usual care arm, mean difference (95% CI) - 1148 mL (- 2200 to - 96) mL, P = 0.033. Median [IQR] duration of AKI …
RESULTS: Mean (SD) cumulative fluid balance at 72 h from randomization was - 1080 mL (2003 mL) in the restrictive fluid management arm and 6 …
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Schultz LM, et al. J Clin Oncol. 2022 Mar 20;40(9):945-955. doi: 10.1200/JCO.20.03585. Epub 2021 Dec 9. J Clin Oncol. 2022. PMID: 34882493 Free PMC article.
Univariate and multivariate analyses associate high-disease burden (HB, 5% bone marrow lymphoblasts, CNS3, or non-CNS extramedullary) with inferior outcomes, with a 12-month OS of 58% and EFS of 31% compared with low-disease burden (OS; 85%, EFS; 70%) and undetectable disease (OS …
Univariate and multivariate analyses associate high-disease burden (HB, 5% bone marrow lymphoblasts, CNS3, or non-CNS extramedullary) with i …
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Kelly K, et al. J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324372 Clinical Trial.
There was no statistically significant difference in DFS (median, 50.5 months for erlotinib and 48.2 months for placebo; hazard ratio, 0.90; 95% CI, 0.74 to 1.10; P = .324). Among the 161 patients (16.5%) in the EGFRm-positive subgroup, DFS favored erlotinib (median, 46.4 …
There was no statistically significant difference in DFS (median, 50.5 months for erlotinib and 48.2 months for placebo; hazard ratio, 0.90; …
Development of a Culturally-Adapted Graphic Novella about Emergency Communication: Collaborations with a Limited English Speaking Chinese Immigrant Community.
Eisenberg D, Seino L, Meischke H, Tu SP, Turner AM, Ike B, Painter I, Yip MP. Eisenberg D, et al. J Health Care Poor Underserved. 2016;27(3):1199-210. doi: 10.1353/hpu.2016.0116. J Health Care Poor Underserved. 2016. PMID: 27524762
We used a cultural adaptation approach to develop a graphic novella for Chinese LEP immigrants about how to call 911 and perform bystander CPR. Collaboration with members of this community occurred through all stages of novella development. One hundred and thirty-tw …
We used a cultural adaptation approach to develop a graphic novella for Chinese LEP immigrants about how to call 911 and perform byst …
Degradation of monocrotophos by Starkeya novella YW6 isolated from paddy soil.
Sun L, Zhu S, Yang Z, Chen Q, Liu H, Zhang J, Hu G, Li S, Hong Q. Sun L, et al. Environ Sci Pollut Res Int. 2016 Feb;23(4):3727-35. doi: 10.1007/s11356-015-5606-0. Epub 2015 Oct 24. Environ Sci Pollut Res Int. 2016. PMID: 26498809
A bacteria strain, YW6, capable of utilizing monocrotophos (MCP) as the sole carbon and nitrogen sources for growth was isolated from paddy soil and identified as Starkeya novella. Strain YW6 completely degraded 0.2 mM MCP within 36 h without any lag period. ...In addition …
A bacteria strain, YW6, capable of utilizing monocrotophos (MCP) as the sole carbon and nitrogen sources for growth was isolated from paddy …
Structure of the active site of sulfite dehydrogenase from Starkeya novella.
Doonan CJ, Kappler U, George GN. Doonan CJ, et al. Inorg Chem. 2006 Sep 4;45(18):7488-92. doi: 10.1021/ic0607944. Inorg Chem. 2006. PMID: 16933953
In this paper, we report the results of molybdenum K-edge X-ray absorption studies performed on the oxidized and reduced active sites of the sulfite dehydrogenase from Starkeya novella. Our results provide the first direct structural information on the active site of the o …
In this paper, we report the results of molybdenum K-edge X-ray absorption studies performed on the oxidized and reduced active sites of the …
Frailty in mouse ageing: A conceptual approach.
von Zglinicki T, Varela Nieto I, Brites D, Karagianni N, Ortolano S, Georgopoulos S, Cardoso AL, Novella S, Lepperdinger G, Trendelenburg AU, van Os R. von Zglinicki T, et al. Mech Ageing Dev. 2016 Dec;160:34-40. doi: 10.1016/j.mad.2016.07.004. Epub 2016 Jul 18. Mech Ageing Dev. 2016. PMID: 27443148 Free article. Review.
344 results